Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with <i>IDH1</i>-mutant acute myeloid leukemia-Reference-Cited by-同舟云学术

Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia

Published:2022-12-09 Issue:2 Volume:64 Page:454-461
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Bewersdorf Jan Philipp¹^ORCID,Patel Kishan K.²,Goshua George³⁴,Shallis Rory M.³⁵^ORCID,Podoltsev Nikolai A.³⁵,Stahl Maximilian⁶,Stein Eytan M.¹,Huntington Scott F.³⁵,Zeidan Amer M.³⁵

Affiliation:

1. Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

2. Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA

3. Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA

4. Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA

5. Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA

6. Department of Medical Oncology, Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USA

Funder

Frederick A. DeLuca Foundation

American Society of Hematology Physician-Scientist Career Development Award

National Cancer Institute (NCI) Cancer Clinical Investigator Team Leadership Award

NCI, National Institutes of Health

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2140288

Reference28 articles.

1. Isocitrate dehydrogenase mutations in myeloid malignancies

2. Ivosidenib and Azacitidine inIDH1-Mutated Acute Myeloid Leukemia

3. Durable Remissions with Ivosidenib inIDH1-Mutated Relapsed or Refractory AML

4. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

5. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3- mutant acute myeloid leukemia;Leukemia & Lymphoma;2024-04-22

2. Ivosidenib–azacitidine dans les leucémies aiguës myéloïdes avec mutation IDH1 R132;Bulletin du Cancer;2023-12

3. Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?;Journal of the National Comprehensive Cancer Network;2023-05